Can Allegro’s Integrin Peptide Therapy Help Usher in Retina 2.0 for Vitreoretinal Indications?


Allegro Ophthalmics’ executive team boasts a successful pedigree that began with starting ISTA and taking it public. Now, Vicken Karageozian, MD, president and CMO, says the company is six months away from receiving results from Phase II trials. Hear how the firm has advanced this promising new drug without venture capital.

Podcast Guest

Vicken Karageozian, MD

Vicken Karageozian, MD, is president and chief medical officer of Allegro Ophthalmics. Dr. Karageozian has more than 22 years’ experience building and leading companies in the ophthalmic pharmaceutical space.

View Full Profile